• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Chance of Alzheimer's Disease Diagnosis is Higher in Older Adults with COVID-19

Article

Data was collected by researchers to understand the underlying mechanisms and for continuous surveillance of long-term impacts of COVID-19 on Alzheimer’s disease.

Older adults with COVID-19 have a higher chance of being diagnosed with Alzheimer's disease, according to researchers at Case Western University.

Data was collected by researchers to understand the underlying mechanisms and for continuous surveillance of long-term impacts of COVID-19 on Alzheimer’s disease. It was then shared in a study recently published in the Journal of Alzheimer’s Disease.

The study reported that those 65 and older with COVID had more of a chance to develop Alzheimer's in the year following their COVID diagnosis. Patients most at threat were women 85 years and older.

These results were found and collected in the retrospective cohort study of over 6.2 million older adults 65 years and older who had medical encounters between February 2020 to May 2021.

Researchers used an analytics platform to access de-identified electronic health records of over 95 million patients of both inpatient and outpatient visits from 68 healthcare organizations, representing 28% of the U.S. population from 50 states covering different geographic, age, race/ethnic, income and insurance groups.

Data shared that the COVID-19 cohort did not differ in age nor gender from the non-COVID-19 cohort, but comprised more Hispanic and Black people and had higher prevalence of adverse socioeconomic determinants of health and comorbidities

However, whether COVID-19 might trigger new-onset Alzheimer’s disease or accelerate its emergence is unclear, the study said.

Researchers suggest the next steps in this investigation include validation from other data resources, longer-term follow-up, mechanism understanding and examining other types of dementia


Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.